Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benign and hyperplastic endometrial changes associated with tamoxifen use

R R Barakat1

  • 1Gynecology Service, Memorial Sloan-Kettering Cancer Center, New York, USA.

Oncology (Williston Park, N.Y.)
|February 1, 1997
PubMed
Summary

Tamoxifen, used for breast cancer, can affect the endometrium, increasing risks of polyps, hyperplasia, and cancer. Further research is needed to establish routine gynecologic screening protocols for patients on this medication.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimal (≤1 cm) but visible residual disease: is extensive debulking warranted?

Gynecologic oncology·2013
Same author

Positive peritoneal cytology is highly predictive of prognosis and relapse patterns in stage III (FIGO 2009) endometrial cancer.

Gynecologic oncology·2013
Same author

Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer.

Gynecologic oncology·2013
Same author

Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: review of surgical technique, complications, and outcome.

Gynecologic oncology·2012
Same author

Reproductive outcomes of patients undergoing radical trachelectomy for early-stage cervical cancer.

Gynecologic oncology·2012
Same author

Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: an update on out of the box surgery.

Gynecologic oncology·2012

Area of Science:

  • Oncology
  • Gynecology

Background:

  • Tamoxifen is a widely used breast cancer treatment with known effects on the endometrium.
  • It acts as a mixed estrogen agonist/antagonist, leading to endometrial proliferation.
  • Tamoxifen use is linked to increased risks of endometrial polyps, hyperplasia, and endometrial cancer.

Purpose of the Study:

  • To evaluate the established utility of routine gynecologic screening in breast cancer patients undergoing tamoxifen therapy.
  • To determine the role of transvaginal sonography in detecting endometrial changes and establish appropriate intervention cut-off points.
  • To assess the effectiveness of routine office endometrial biopsy as a screening method.

Main Methods:

  • Review of existing literature and clinical data regarding tamoxifen's endometrial effects.

Related Experiment Videos

  • Analysis of the diagnostic capabilities of transvaginal sonography for endometrial proliferation.
  • Evaluation of the potential for routine endometrial biopsy as a screening tool.

    • Main Results:

    • Tamoxifen is associated with a higher incidence of endometrial polyps and hyperplasia compared to controls.
    • A slightly increased risk of endometrial cancer has been observed in patients using tamoxifen.
    • Transvaginal sonography is effective in detecting endometrial proliferation, but optimal cut-off points for intervention require further definition.

    Conclusions:

    • The necessity of annual gynecologic exams and aggressive follow-up for abnormal bleeding in tamoxifen patients requires further investigation.
    • Establishing appropriate transvaginal sonography cut-off points is crucial to avoid unnecessary endometrial biopsies.
    • Routine office endometrial biopsy requires additional study as a screening method for breast cancer patients on tamoxifen.